Bayer AG Stock
Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Pros and Cons of Bayer AG in the next few years
Pros
Cons
Performance of Bayer AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bayer AG | 0.480% | -3.755% | 0.574% | -57.269% | -21.917% | -51.406% | -57.311% |
| Merck KGaA | 0.210% | -3.907% | -6.396% | -10.599% | 1.667% | -1.910% | 55.427% |
| Elanco Animal Health Inc. | -6.370% | -7.271% | -12.163% | 50.047% | -5.666% | -49.025% | - |
| Pfizer Inc. | 2.180% | -2.851% | -6.654% | -35.541% | -8.621% | -25.863% | -28.239% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.From an initial glance at the financials of Bayer (BAYZF), it's evident that the company has a significant market presence in the pharmaceuticals industry, boasting a diverse asset portfolio and robust revenues. However, while the company exhibits resilience and growth potential, it also faces notable challenges, particularly in areas such as debt, net income fluctuations, and operational expenditures.
Revenue growth: Bayer has shown a consistent increase in total revenue over the past three years, from €41.4 billion in 2020 to €44.08 billion in 2021, and €50.74 billion in 2022. This trend indicates that the company is maintaining strong market performance, with potential for further revenue growth.
Asset base: Bayer has a substantial asset base, with the total assets increasing from €117.05 billion in 2020 to €120.24 billion in 2021, and finally to €124.88 billion in 2022. This growth demonstrates the company's ability to effectively manage and expand its operations.
Comments
News
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy